Effects of raloxifene on the production of cytokines in stimulated whole blood in ex vivo and in vitro studies

Journal of Medical Investigation

Volumn 58, Issue 1-2, 2011, Pages 110-117

  Kasai, Yuka ^a   Maegawa, Masahiko ^a   Yamamoto, Satoshi ^b   Kamada, Masaharu ^c   Yasui, Toshiyuki ^b   Uemura, Hirokazu ^b   Kobayashi, Ayako ^b   Kaneyama, Masayo ^b   Tani, Anna ^b   Matsui, Sumika ^b   Kuwahara, Akira ^b   Matsuzaki, Toshiya ^b   Furumoto, Hiroyuki ^b   Irahara, Minoru ^b  

^a TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Health Insurance Naruto Hospital   (Japan)

Author keywords

Cytokine; Raloxifene; Whole blood assay

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; SUPERNATANT; TREATMENT DURATION;

EID: 79951900235     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.58.110     Document Type: Article

References (26)

1. Suenaga R, Evans MJ, Mitamura K, River V, Abdou NI: Peripheral blood T cells and mono-cytes and B-cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J Rheumatol 25: 1305-1312, 1998
2. Straub RH: The complex role of estrogens in inflammation. Endocrine Rev 28: 521- 574, 2007
3. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257: 88-91, 1992
4. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R: Interleukin 1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorp-tion in ovariectomized mice. J Clin Invest 94: 2397-2406, 1994
5. Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, Gonowicz G, Kalinowski J, Pilibeam CC: Mice lacking the type 1 interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139: 3022-3025, 1998
6. Ralston SH, Russell RG, Gowen M: Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in post-menopausal women. J Bone Miner Res 5: 983-988, 1990
7. Rogers A, Eastell R: The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood. Bone 29: 30-34, 2001
8. Matalka KZ: The effect of estradiol, but not progesterone, on the production of cytokines in stimulated whole blood, is concentration-depedent. Neuroendocrinol Lett 24: 185-191, 2003
9. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Murata K, Yasui T, Yamano S, Aono T: Transient increase in the level of T-helper 1 cy-tokines in postmenopausal women and the effects of hormone replacement therapy. Gyne-col Obstet Invest 52: 82-88, 2001
10. Deguchi K, Kamada M, Irahara M, Maegawa M, Yamamoto S, Ohmoto Y, Murata K, Yasui T, Yamano S, Aono T: Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause 8: 266-273, 2001
11. Uemura H, Kamada M, Maegawa M, Ohmoto Y, Murata K, Kuwahara A, Matsuzaki T, Yasui T, Takeji T, Irahara M: Effect of hormone replacement therapy on the production of bone-resorbing cytokines by peripheral blood cells in postmenopausal women. Horm Metab Res 37: 226-230, 2005
12. Petrovsky N, Harrison LC: Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. J Immunol Meth 186: 37-46,1995
13. Petrovsky N, Harrison LC: Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper type 2 balance? J Immunol 158:163-168,1997
14. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW: Role of tumor necrosis factor- and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88: 825-828, 2001
15. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, Patane F, Agliano AM, Spera G, Marigliano V, Ammendola S, Agnusdei D, Migliaccio S, Scandurra R: Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 89:6079-6099, 2004
16. Ozmen B, Kirmaz C, Aydin K, Kafescller SO, Guclu F, Hekimsoy Z: Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-a, TGF-p1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 18:148-153, 2007
17. Yasui T, Uemura H, Hyodo S, Yamada M, Yamamoto S, Maegawa M, Tsuchiya N, Noguchi M, Yuzurihara M, Kase Y, Irahara M: Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women. Atherosclerosis 204: 471-475,2009
18. Rogers A, Clowes JA, Pereda CA, Eastell R: Different effects of raloxifene and estrogen on interleukin-1p and interleukin-1 receptor antagonist production using in vitro and ex vivo studies. Bone 40:105-110, 2007
19. De Groote D, Zangerle PF, Genaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I: Direct stimulation of cytokines (IL-1B, TNF-a, IL-6, IL-2, IFN-y and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 4:239-248,1992
20. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application: Eur J Obstet Gnyecol Reprod Biol 85: 23-29, 1999.
21. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S: The selective estrogen receptor modulator raloxifene regulates osteo-clast and osteoblast activity in vitro. Bone 30: 368-376, 2002
22. Cheung J, Mak YT, Papaioannou S, Evans BAJ, Fogelman I, Hampson G: Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 177: 423-433, 2003
23. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549, 1993
24. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991
25. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, Crane M, Kanik KS, Chrousos GP: IL-12, TNF-α and hormonal changes during late pregnancy and early post-partum: Implication for autoimmune disease activity during these times. J Clin Endocrinol Metab 86: 4933-4938, 2001
26. Kumru S, Yildiz FM, Godekmerdan A, Kutlu S, Yilmaz B, Gurates B: Effects of raloxifene and hormone replacement therapy of serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomized controlled trial. Arch Gynecol Obstet 277: 489-493, 2008